AstraZeneca Long-Term Investments 2010-2024 | AZN

AstraZeneca long-term investments from 2010 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
  • AstraZeneca long-term investments for the quarter ending September 30, 2024 were $2.464B, a 70.99% increase year-over-year.
  • AstraZeneca long-term investments for 2023 were $1.905B, a 56.66% increase from 2022.
  • AstraZeneca long-term investments for 2022 were $1.216B, a 9.19% decline from 2021.
  • AstraZeneca long-term investments for 2021 were $1.339B, a 1.59% increase from 2020.
AstraZeneca Annual Long-Term Investments
(Millions of US $)
2023 $1,905
2022 $1,216
2021 $1,339
2020 $1,318
2019 $1,520
2018 $1,079
2017 $1,540
2016 $1,169
2015 $989
2014 $1,026
2013 $646
2012 $588
2011 $543
2010 $535
2009 $184
AstraZeneca Quarterly Long-Term Investments
(Millions of US $)
2024-09-30 $2,464
2024-06-30 $2,088
2024-03-31 $1,908
2023-12-31 $1,905
2023-09-30 $1,441
2023-06-30 $1,143
2023-03-31 $1,350
2022-12-31 $1,216
2022-09-30 $1,214
2022-06-30 $1,293
2022-03-31 $1,324
2021-12-31 $1,339
2021-09-30 $1,675
2021-06-30 $1,244
2021-03-31 $1,175
2020-12-31 $1,318
2020-09-30 $1,334
2020-06-30 $1,618
2020-03-31 $1,624
2019-12-31 $1,520
2019-09-30 $1,392
2019-06-30 $1,559
2019-03-31 $1,700
2018-12-31 $1,079
2018-09-30 $1,683
2018-06-30 $1,705
2018-03-31 $1,768
2017-12-31 $1,540
2017-09-30 $1,522
2017-06-30 $1,411
2017-03-31 $1,137
2016-12-31 $1,169
2016-09-30 $1,088
2016-06-30 $912
2016-03-31 $1,023
2015-12-31 $989
2015-09-30 $971
2015-06-30 $971
2015-03-31 $1,033
2014-12-31 $1,026
2014-09-30 $737
2014-06-30 $708
2014-03-31 $649
2013-12-31 $646
2013-09-30 $564
2013-06-30 $604
2013-03-31 $628
2012-12-31 $588
2012-09-30 $502
2012-06-30 $491
2012-03-31 $530
2011-12-31 $543
2011-09-30 $562
2011-06-30 $537
2011-03-31 $504
2010-12-31 $211
2010-09-30 $205
2010-06-30 $563
2010-03-31 $479
2009-12-31 $184
2009-09-30 $534
2009-06-30 $456
2009-03-31 $565
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $197.819B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94